1. Biochemistry
  2. Cell Biology
Download icon

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

  1. Anil M Narasimha
  2. Manuel Kaulich
  3. Gary S Shapiro
  4. Yoon J Choi
  5. Piotr Sicinski
  6. Steven F Dowdy Is a corresponding author
  1. University of California, San Diego School of Medicine, United States
  2. Harvard Medical School, United States
  3. Dana-Farber Cancer Institute, United States
Research Article
Cited
30
Views
7,417
Comments
0
Cite as: eLife 2014;3:e02872 doi: 10.7554/eLife.02872

Abstract

The widely accepted model of G1 cell cycle progression proposes that cyclin D:Cdk4/6 inactivates the Rb tumor suppressor during early G1 phase by progressive multi-phosphorylation, termed hypo-phosphorylation, to release E2F transcription factors. However, this model remains unproven biochemically and the biologically active form(s) of Rb remains unknown. In this study, we find that Rb is exclusively mono-phosphorylated in early G1 phase by cyclin D:Cdk4/6. Mono-phosphorylated Rb is composed of 14 independent isoforms that are all targeted by the E1a oncoprotein, but show preferential E2F binding patterns. At the late G1 Restriction Point, cyclin E:Cdk2 inactivates Rb by quantum hyper-phosphorylation. Cells undergoing a DNA damage response activate cyclin D:Cdk4/6 to generate mono-phosphorylated Rb that regulates global transcription, whereas cells undergoing differentiation utilize un-phosphorylated Rb. These observations fundamentally change our understanding of G1 cell cycle progression and show that mono-phosphorylated Rb, generated by cyclin D:Cdk4/6, is the only Rb isoform in early G1 phase.

https://doi.org/10.7554/eLife.02872.001

eLife digest

Cells go through a tightly controlled, multi-step procedure before they divide. This cell division program—the cell cycle—is necessary for preventing unrestrained cellular growth, which may lead to cancer. Proteins called cyclins control the progression through each of the phases of the cell cycle, with different cyclins working during different phases.

During the G1 phase of the cell cycle, cells grow in size and produce the proteins that are required to copy DNA. Once a cell passes a checkpoint called the 'restriction point' at the end of the G1 phase, it is committed to dividing. It is therefore particularly important to keep events during G1 phase in check.

The Retinoblastoma tumor suppresor protein (Rb) is a key player in regulating the G1 phase. Rb sequesters transcription factors that are essential for the cell cycle to progress. Previously, it was thought that a complex called cyclin D added more and more phosphates to the Rb protein during the G1 phase. This process predicted a slow release of transcription factors, which attach to DNA and start the process of DNA replication. While many studies have presented data that is consistent with this model, direct biochemical evidence of these events is lacking.

Narasimha, Kaulich, Shapiro et al. now present biochemical analyses of Rb proteins that show—completely unexpectedly—that the cyclin D complex adds just one phosphate group to Rb during the G1 phase, although this group can be added to one of fourteen different sites. The resulting 'mono-phosphorylated' Rb varieties can each sequester different transcription factors and stop them working.

At the restriction point, many more phosphate groups are then rapidly added, and the Rb protein is inactivated by a different cyclin. This cyclin—called Cyclin E—then drives cells into the next phase of the cell cycle. Establishing how cyclin E is activated is a priority for future research.

https://doi.org/10.7554/eLife.02872.002

Introduction

The retinoblastoma tumor suppressor protein (Rb) functions to regulate multiple critical cellular activities, including the late G1 restriction point, the DNA damage response checkpoint, cell cycle exit, and differentiation (Burkhart and Sage, 2008; Paternot et al., 2010; Henley and Dick, 2012; Johnson and Skotheim, 2013). However, the Rb gene is infrequently mutated or deleted, instead upstream pathways that regulate Rb by phosphorylation on Cdk sites are altered in the majority of human cancers, including deletion and mutation of the p16 tumor suppressor and upregulation and mutation of cyclin D1, D2, D3, Cdk4 and Cdk6 genes (Sherr and McCormick, 2002; Knudsen and Knudsen, 2006; Burkhart and Sage, 2008; Henley and Dick, 2012; Choi and Anders, 2013). Rb contains 16 putative Cdk phosphorylation sites that are spread throughout the protein, and all but one (S567) lie outside of Rb's structured A'/B' and A/B-box or ‘pocket’ protein–protein binding domains (Figure 1A). Rb is thought to exist in three generalized isoforms: (1) un-phosphorylated Rb; (2) hypo-phosphorylated Rb, also referred to as ‘under’ phosphorylated Rb or ‘partially’ phosphorylated Rb; and (3) inactive hyper-phosphorylated Rb, present in late G1, S, G2 and M phases that is readily identifiable by SDS-PAGE as a slower migrating species (Burkhart and Sage, 2008; Paternot et al., 2010; Henley and Dick, 2012). Surprisingly, given the scientific scrutiny of Rb over the last 25 years, the biochemical identification of the biologically active isoform(s) of Rb required for early G1 phase regulation, DNA damage checkpoint control, cell cycle exit, and differentiation remains unknown.

To dissect Rb function and regulation, many early reports utilized supra-physiologic overexpression studies using various cyclins (A, B, D, E) and Cdks (−1, −2, −4, −6) that resulted in Rb inactivation by hyper-phosphorylation associated with an accelerated S-phase entry, and induction of E2F-dependent target genes (Hinds et al., 1992; Ewen et al., 1993; Resnitzky et al., 1994; Lundberg and Weinberg, 1998). Likewise, supra-physiologic overexpression studies using Rb constructs where many, but not all, of the putative Cdk Ser/Thr consensus sites were mutated to Ala residues resulted in repressed E2F-dependent transcription and cell cycle arrest, as did overexpression of Cdk inhibitors, p16, p21, and p27 (Sherr, 1994; Knudsen and Wang, 1997; Leng et al., 1997; Sherr and McCormick, 2002; Knudsen and Knudsen, 2006; Burkhart and Sage, 2008; Paternot et al., 2010; Henley and Dick, 2012; Choi and Anders, 2013). Collectively, over the last 20 years, these studies have led to a widely accepted model of G1 cell cycle progression that proposes cyclin D:Cdk4/6 inactivates Rb during early G1 phase by progressive multi-phosphorylation, termed ‘hypo-phosphorylation’, resulting in release of E2F transcription factors that induce expression of cyclin E, resulting in activation of cyclin E:Cdk2 complexes that complete Rb inactivation by hyper-phosphorylation in late G1 phase. The key tenet of this model is the progressive multi-phosphorylating, hypo-phosphorylation of Rb by cyclin D:Cdk4/6 complexes; however, the putative hypo-phosphorylated Rb and un-phosphorylated Rb co-migrate on 1D SDS-PAGE and cannot be separated (Ezhevsky et al., 2001). Moreover, there is no biochemical data defining the extent or timing of phosphorylation that constitutes hypo-phosphorylated Rb. Consequently, it remains entirely unknown if hypo-phosphorylated Rb contains one, two, three, five, seven or more phosphates and at what phosphate number does the putative hypo-phosphorylated Rb become inactive to release E2F transcription factors. Thus, the critical core tenet of the G1 model that cyclin D:Cdk4/6 inactivates Rb by progressive multi-phosphorylation or hypo-phosphorylation remains unproven biochemically.

We have previously found in kinetic analyses from highly synchronized normal cells and p16-deficient cancer cells that cyclin D:Cdk4/6 is constitutively active throughout early G1 phase at the same time when Rb is repressing E2F target genes (Ezhevsky et al., 1997, 2001; Haberichter et al., 2007). In fact, we only observed induction of E2F target genes upon the activation of cyclin E:Cdk2 complexes and the appearance of hyper-phosphorylated Rb. These observations questioned the core biological consequences of cyclin D:Cdk4/6 progressive hypo-phosphorylation of Rb during early G1 phase. Here, for the first time, we separated all Rb isoforms by two-dimensional isoelectric focusing (2D IEF) and find that Rb is exclusively mono-phosphorylated in early G1 phase in both normal and p16-deficient tumor cells. We found no experimental evidence to support the notion of progressive multi-phosphorylating hypo-phosphorylation of Rb. Using Cdk4/6-specific inhibitors and triple cyclin D-deleted MEFs, we determined that cyclin D:Cdk4/6 is the Rb mono-phosphorylating kinase that generates 14 independent mono-phosphorylated Rb isoforms in early G1 phase. At the late G1 Restriction Point, activation of cyclin E:Cdk2 complexes perform a quantum hyper-phosphorylating inactivation of all mono-phosphorylated Rb isoforms. Cells undergoing a DNA damage response activate cyclin D:Cdk4/6 complexes to generate active mono-phosphorylated Rb that regulates global transcription, whereas cells exiting the cell cycle use un-phosphorylated Rb. Together, our observations demonstrate that mono-phosphorylated Rb, generated by cyclin D:Cdk4/6 complexes, is the functionally active Rb isoform present in early G1 phase.

Results

Un-phosphorylated, mono-phosphorylated, and hyper-phosphorylated Rb isoforms

Rb contains 15 putative Cdk phosphorylation sites located on loops between or after structured A'/B' and A/B pocket domains (Burke et al., 2012; Lamber et al., 2013) (Figure 1A). Rb is thought to exist in three generalized biochemical states: un-phosphorylated Rb; progressive hypo-phosphorylated Rb (also termed ‘under’ or ‘partially’ phosphorylated Rb); and inactive hyper-phosphorylated Rb (Lee et al., 1987; DeCaprio et al., 1989; Ludlow et al., 1989; Mittnacht et al., 1994; Ezhevsky et al., 2001). Although early G1 phase Rb hypo-phosphorylation was first reported 25 years ago (Ludlow et al., 1989), the actual number, kinetics and location of phosphates on hypo-phosphorylated Rb remains entirely unknown. Analysis of synchronized primary human foreskin fibroblasts (HFFs) arrested in early G1 phase by contact inhibition in the presence of serum and released by replating at low density progressed through early G1 phase with constitutively active cyclin D:Cdk4/6 complexes and no evidence for increased Rb phosphorylation or transcriptional induction of Cdc6, a key E2F target gene repressed by active Rb (Morris and Dyson, 2001) (Figure 1B). In contrast, Cdc6 was induced ten-fold upon cyclin E:Cdk2 activation and Rb hyper-phosphorylation, which migrates more slowly on 1D SDS-PAGE. However, the putative hypo-phosphorylated Rb isoforms co-migrated as a single fastest migrating species during all of the early G1 phase time points (Figure 1B). Thus, there is either no evidence for progressive hypo-phosphorylation of Rb and/or 1D SDS-PAGE is not capable of separating all Rb phospho-isoforms.

Figure 1 with 1 supplement see all
Rb is exclusively mono-phosphorylated in early G1 phase.

(A) Schematic diagram of human Rb Cdk phosphorylation sites, A'/B' and A/B pocket domains. (B) Kinetic analysis of contact inhibited early G1 phase arrested (+FBS) and released primary Human Fibroblasts (HFFs) by 1D SDS-PAGE Rb immunoblot, anti-Cdk4/6, and anti-Cdk2 immunoprecipitation-kinase assay, and qRT-PCR of cyclin E and cdc6 mRNA normalized to B-2-microglobulin levels. (C) Schematic diagram of two-dimensional isoelectric focusing (2D IEF). Immunoprecipitated Rb is loaded at origin on acidic end of IEF strip and separated first by pI. IEF strip is then soaked in SDS, run in second dimension into SDS-PAGE and immunoblotted for Rb. (D) 2D IEF Rb-HA immunoblot of Rb construct standards expressed in cycling cells and containing 0 (ΔCdk), 1x, 2x, 3x, 6x, 9x or 15x Cdk phosphorylation sites. (E) Top panels: 2D IEF Rb immunoblot of primary HFFs serum deprived G0 arrested (−FBS), contact inhibited early G1 phase arrested (+FBS), or asynchronously cycling. Bottom panels: 2D IEF Rb immunoblot of serum deprived G0 arrested (−FBS) HFFs mixed with ΔCdk Rb standard, contact inhibited early G1 phase arrested (+FBS) HFFs mixed with single Cdk site Rb standard and contact inhibited treated with λ phosphatase. (F) 2D IEF Rb immunoblot from cycling human tumor cell lines expressing wild-type Rb and deregulated cyclin D:Cdk4/6 due to p16 deletion, HCT116 colon carcinoma, H1299 lung adenocarcinoma, U2OS osteosarcoma, HL60 promyelocytic leukemia. (G) 2D IEF Rb immunoblot from serum deprived G0 arrested (−FBS) and released (+FBS) primary HFFs from 0 to 16 hr (H) 2D IEF Rb immunoblot from contact inhibited early G1 phase arrested (+FBS) and released HFFs from 0 to 10 hr (I) 2D IEF Rb immunoblot from contact inhibited early G1 phase arrested (+FBS) and released U2OS from 0 to 10 hr.

https://doi.org/10.7554/eLife.02872.003

Phosphates are highly acidic modifications that significantly change the isoelectric point (pI) of a protein. Unlike 1D SDS-PAGE, two-dimensional isoelectric focusing (2D IEF) can separate specific phospho-isoforms of a protein based on total phosphate numbers regardless of position within the protein or nature of the modified residue (Figure 1C). Therefore, we utilized 2D IEF to ascertain the extent and kinetics of the putative progressive multi-phosphorylated hypo-phosphorylation of Rb during early G1 phase. First, we calibrated the 2D IEF by generating a non-phosphorylatable Rb construct (ΔCdk Rb) standard where 15 of the 16 putative Cdk sites were converted to Ala residues (Figure 1A), plus we added an N-terminal HA tag. We left S567 unaltered because it is buried in the central core of Rb's A-box and solvent inaccessible (Lee et al., 1998). The isoelectric point of un-phosphorylated Rb is 8.1, and 2D IEF of the ΔCdk Rb construct expressed in asynchronous cycling cells focused as a single basic species with a pI ∼8 (Figure 1D), confirming that Rb is only phosphorylated on Cdk sites and that S567 is not phosphorylated in vivo.

Starting with ΔCdk Rb, we generated Rb phospho-isoform standards by restoring one (Rb1xCdk), two (Rb2xCdk), three (Rb3xCdk), six (Rb6xCdk), nine (Rb9xCdk), or fifteen (Rb15xCdk) Cdk sites on Rb. 2D IEF of single Cdk site Rb1xCdk construct expressed in cycling cells focused as a single phosphorylated Rb species with a more acidic pI ∼7.0, that we termed mono-phosphorylated Rb (Figure 1D). The double Cdk site Rb2xCdk construct focused as two spots: mono-phosphorylated Rb and di-phosphorylated Rb. Surprisingly, 2D IEF of the Rb3xCdk construct focused as mono-phosphorylated and tri-phosphorylated Rb, with no di-phosphorylated Rb (Figure 1D). Likewise, 2D IEF of Rb constructs containing six (Rb6xCdk), nine (Rb9xCdk) and fifteen (Rb15xCdk) Cdk sites resulted in the appearance of mono-phosphorylated Rb, plus either a six, nine, or >12 phosphate (pI < 4) Rb species, respectively, and the absence of any intermediate Rb phospho-isoforms (Figure 1D). Thus, unlike 1D SDS-PAGE, 2D IEF quantitatively separated all Rb isoforms from un-phosphorylated Rb to mono-phosphorylated Rb and all multi-phosphorylated Rb isoforms up to hyper-phosphorylated Rb.

We next analyzed endogenous, wild-type Rb from primary HFFs by 2D IEF. Consistent with no 32P-labeling of Rb from G0 arrested cells (DeCaprio et al., 1989; Ezhevsky et al., 2001), Rb from serum deprived G0 arrested primary HFFs focused as a single, basic isoform with a pI ∼8 (Figure 1E). 2D IEF of Rb from G0-arrested primary HFFs mixed with non-phosphorylatable ΔCdk Rb standard, co-focused as a single un-phosphorylated Rb species. In contrast, Rb from contact inhibited early G1 phase arrested (+FBS) HFFs focused as a single mono-phosphorylated species with a pI ∼7.0 (Figure 1E). 2D IEF of Rb from contact inhibited HFF Rb mixed with the single Rb1xCdk construct standard confirmed that contact inhibited cells contain only mono-phosphorylated Rb. Lambda phosphatase treatment of contact inhibited mono-phosphorylated Rb collapsed into un-phosphorylated Rb (Figure 1E). 2D IEF of Rb from asynchronously cycling primary HFFs focused as two isoforms: mono-phosphorylated Rb plus a very acidic hyper-phosphorylated Rb isoform (pI < 4) (Figure 1E).

The majority of human tumors expressing wild-type Rb contain oncogenic mutations that upregulate cyclin D:Cdk4/6 kinase activity (Sherr and McCormick, 2002; Choi and Anders, 2013). We examined four disparate human tumor cell lines that express wild-type Rb, and are deleted for the p16 tumor suppressor gene, a specific inhibitor of Cdk4/6. Surprisingly, 2D IEF of Rb from cycling populations of all four tumor cell lines, HCT116 colon carcinoma, H1299 lung adenocarcinoma, U2OS osteosarcoma, and HL60 promyelocytic leukemia, showed the presence of only mono-phosphorylated Rb and hyper-phosphorylated Rb, with no evidence of multi-phosphorylated, hypo-phosphorylated Rb isoforms, even though cyclin D:Cdk4/6 was deregulated in all four tumor cell types (Figure 1F). Together, these results present several significant insights into the biochemical properties of Rb phosphorylation in vivo. First, G0-arrested cells contain un-phosphorylated Rb. Second, Rb from both cycling normal and p16-deleted tumor cells is only mono-phosphorylated or hyper-phosphorylated in vivo. Third, these observations point to phosphorylation of Rb by two entirely independent cyclin:Cdk activities: (1) a Rb mono-phosphorylating Cdk activity that places one, and only one, phosphate on Rb; and (2) a Rb hyper-phosphorylating Cdk activity that places >12 phosphates on Rb.

Rb is exclusively mono-phosphorylated in early G1 phase of normal and tumor cells

The current widely accepted model of G1 cell cycle progression proposes that Rb becomes progressively more hypo-phosphorylated by cyclin D:Cdk4/6 complexes as cells advance through early G1 phase. To test this notion, we performed kinetic analyses on HFF cells arrested in G0 by serum deprivation and restimulated by serum addition (+FBS) to enter early G1 phase (Figure 1G). G0 cells contained only un-phosphorylated Rb, but by 1 hr post-stimulation, a small amount of mono-phosphorylated was detected, concurrent with activation of cyclin D:Cdk4/6 complexes (Figure 1—figure supplement 1A). By 3 hr, only mono-phosphorylated Rb was present. Surprisingly, Rb remained exclusively mono-phosphorylated throughout the entire early G1 phase time points at 3, 4, 5, 6, 8, 10, 12. and 14 hr with no higher order phosphorylation species detected (Figure 1G), even though cyclin D:Cdk4/6 complexes were constitutively active. At 16 hr post-release, we detected a quantum switch-like shift to hyper-phosphorylated Rb concomitant with activation of cyclin E:Cdk2 complexes (Figure 1—figure supplement 1A). We next performed a kinetic analysis on primary HFFs arrested in early G1 phase by contact inhibition (+FBS) and released by replating at low density. Rb remained exclusively mono-phosphorylated throughout the entire early G1 phase time points from 0 to 7 hr with no higher order Rb phosphorylation species detected (Figure 1H). Cyclin D:Cdk4/6 kinase activity was constitutively active in contact arrested early G1 phase cells and throughout all of early G1 phase with no detectable cyclin E:Cdk2 kinase activity (Figure 1B). At 10 hr post-release, we detected a strong shift to hyper-phosphorylated Rb (>12 phosphates), concomitant with activation of cyclin E:Cdk2 complexes and transcriptional induction of cdc6, an E2F target gene (Figure 1B). Again, we surprisingly did not detect any evidence for the progressive multi-phosphorylation or hypo-phosphorylation of Rb in early G1 phase or increases in E2F target genes, even though cyclin D:Cdk4/6 complexes were constitutively active.

We next examined synchronized p16-deleted human U2OS osteosarcoma tumor cells (Figure 1I). Contact inhibited early G1-arrested U2OS cells (+FBS) contained only mono-phosphorylated Rb, with no higher order Rb phosphorylated species, and active cyclin D:Cdk4/6 complexes (Figure 1—figure supplement 1B). Rb remained exclusively mono-phosphorylated throughout all of the early G1 phase time points at 1, 2, 3, 4, 5, 6, 7, and 8 hr in the presence of constitutively active cyclin D:Cdk4/6 complexes with no evidence of progressive hypo-phosphorylation. We first detected hyper-phosphorylated Rb at 10 hr post-release (Figure 1I). Together, these observations demonstrated that both primary and tumor cells exclusively generate mono-phosphorylated Rb during all of early G1 phase before being converted in a quantum step to hyper-phosphorylated Rb at the late G1 phase Restriction Point. Collectively, we performed hundreds of 2D IEFs on Rb from 11 cell types and found no biochemical evidence to support the notion of progressive multi-phosphorylation or hypo-phosphorylation of Rb in early G1 phase.

Early G1 phase cells contain fourteen independent mono-phosphorylated Rb isoforms

In all of our 2D IEFs of Rb, we detected one, and only one, phosphate on Rb during early G1 phase. However, Mittnacht et al. (1994) reported that tryptic phospho-peptide mapping (where the 32P-labeled protein is cleaved into small peptides by trypsin digestion and then separated by charge and hydrophobicity) of total Rb isolated from early G1 phase cells (labeled as hypo-phosphorylated Rb) retained the vast majority of the same phospho-peptide spots that hyper-phosphorylated Rb contained. In light of our new observations showing only mono-phosphorylated Rb present in early G1 phase, the Mittnacht et al. (1994) study suggested the potential for the presence of many mono-phosphorylated Rb isoforms that when summed together would result in the observed phospho-peptide pattern.

To ascertain how many of Rb's 15 Cdk sites (Figure 1A) are mono-phosphorylated by cyclin D:Cdk4/6 in early G1 phase, we used a series of phospho-specific Rb antibodies to immunoblot Rb from HFF cells arrested in G0 by serum deprivation (un-phosphorylated Rb) and early G1 phase arrested by contact inhibition (mono-phosphorylated Rb) (Figure 2A). While none of the antibodies recognized un-phosphorylated Rb from G0 arrested HFFs, all of the phospho-specific Rb antibodies recognized mono-phosphorylated Rb isoforms from early G1 phase arrested cells, including S249/S252, T373, S608, S612, S795, S807/S811, T821 and T826 (Figure 2A). Similar mono-phosphorylated Rb isoform results were obtained from contact inhibited early G1 phase arrested p16-deficient U2OS cells (Figure 2A). We also note that all of the phospho-specific antibodies recognized hyper-phosphorylated Rb from S phase arrested cells (Figure 2—figure supplement 1). Together, these observations suggested the presence of at least 8 individual mono-phosphorylated Rb isoforms.

Figure 2 with 1 supplement see all
Mono-phosphorylated Rb exists as fourteen individual isoforms.

(A) Phospho-specific Rb immunoblot of un-phosphorylated Rb (G0, −FBS) and mono-phosphorylated Rb (contact inhibited early G1, +FBS) from HFF and U2OS cells. (B) T826 and S608 phospho-specific Rb immunoprecipitation of mono-phosphorylated Rb (contact inhibited early G1, +FBS) and hyper-phosphorylated Rb (S phase) from HFF cells, followed by phospho-specific Rb immunoblot analysis, as indicated. Note the absence of other phosphates at these locations on mono-phosphorylated Rb, but present on hyper-phosphorylated Rb. (C) 2D IEF Rb-HA immunoblot of single Cdk site Rb-HA constructs expressed in cycling cells. Numbering indicates single Cdk site location on Rb. (D) Immunoblot of Rb-HA single Cdk site constructs and control ΔCdk Rb construct from co-immunoprecipitated and co-expressed E1a, E2F1, E2F2, E2F3 or E2F4 (Myc tagged) as indicated. Numbering indicates single Cdk site location on Rb. Note that all 14 avidly bind to at least two E2F family members and there are no completely inactive mono-phosphorylated Rb isoforms.

https://doi.org/10.7554/eLife.02872.005

To independently confirm the presence of mono-phosphorylated Rb isoforms, we immunoprecipitated mono-phosphorylated Rb from contact inhibited early G1 phase arrested HFFs with either the T826 or S608 phospho-specific Rb antibodies, and then immunoblotted with five phospho-specific Rb antibodies (Figure 2B). Consistent with the 2D IEF data, the phospho-specific immunoprecipitation of T826 mono-phosphorylated Rb was only recognized by immunoblot with the T826 phospho-specific antibody and not by T373, S608, S612, or S795 phospho-specific antibodies. Likewise, immunoprecipitation of S608 mono-phosphorylated Rb was only recognized by the S608 phospho-specific antibody and not by the other phospho-specific antibodies. In contrast, immunoprecipitated hyper-phosphorylated Rb from S phase arrested HFF cells with either the T826 or S608 phospho-specific antibodies was recognized by multiple phospho-specific antibodies (Figure 2B), supporting the presence of multiple phosphates on individual hyper-phosphorylated Rb molecules. To identify the extent of mono-phosphorylated Rb isoforms, we generated all 15 individual single Cdk site Rb constructs. 2D IEFs on each of the single Cdk site Rb constructs expressed in cells determined that 14 of the single Cdk site Rb constructs were mono-phosphorylated in vivo (Figure 2C). T5, which is not evolutionary conserved below primates, was not phosphorylated. Together, these observations demonstrate the presence of 14 independent mono-phosphorylated Rb isoforms in early G1 phase and explain the large number of Rb tryptic phospho-peptide spots observed by Mittnacht et al. (1994). Moreover, because early G1 phase cells exclusively contain mono-phosphorylated Rb, by definition, some, most or all of the 14 mono-phosphorylated Rb isoforms must be biologically active.

Rb has been shown to bind to four members of the E2F family of transcription factors (E2F1-4) and over 100 additional cellular proteins (Morris and Dyson, 2001). We hypothesized that the generation of 14 mono-phosphorylated Rb isoforms may serve as a post-translational mechanism to diversify Rb from a single un-phosphorylated protein in G0 into 14 independently functionalized mono-phosphorylated Rb isoforms that each bind specific cellular targets during early G1 phase. To test this hypothesis, we independently co-transfected each single Cdk site mono-phosphorylated Rb-HA construct and control un-phosphorylatable ΔCdk Rb-HA into cells co-expressing the E1a oncoprotein or E2F-1, E2F-2, E2F-3, E2F-4 transcription factors (Myc tagged), then individually immunoprecipitated E1a and each E2F, and immunoblotted for the associated Rb mono-phosphorylated isoforms (Figure 2D). Given it's role in driving adenovirus infected quiescent G0 cells (containing un-phosphorylated Rb) into G1 phase and then S phase, it was not too surprising that the E1a oncoprotein bound equally well to un-phosphorylated Rb and all 14 mono-phosphorylated Rb isoforms. This observation also showed that all single Cdk site Rb constructs were correctly folded in vivo.

Surprisingly, we found that none of the mono-phosphorylated Rb isoforms were completely inactive for binding to E2Fs and that each E2F showed a preferential binding specificity for individual mono-phosphorylated Rb isoforms (Figure 2D). While E2F2 and E2F3 showed subtle biases for specific mono-phosphorylated Rb isoforms, E2F1 and E2F4 showed the largest enhanced or decreased binding specificities to each Rb mono-phosphorylated isoform. E2F1 showed enhanced binding to Rb when it was mono-phosphorylated at positions S230, S249, T356 and S612 and decreased avidity when Rb was mono-phosphorylated at positions S608, S795 and T826 (Figure 2D). E2F1 bound all of the other mono-phosphorylated Rb isoforms with comparable avidity as control un-phosphorylated ΔCdk Rb. E2F4 showed enhanced binding when Rb was mono-phosphorylated at positions S230, S788 and S811, and decreased binding when it was mono-phosphorylated at positions S249, T373, S780 and T826 (Figure 2D). While phosphorylation of T373 has recently been singled out as an inactivating phosphorylation on a fragment of Rb (Burke et al., 2012), in our hands E1a, E2F1, E2F2, and E2F3 all bound T373 mono-phosphorylated Rb when the full-length protein was expressed in cells. Together, these observations demonstrated the presence of 14 independent mono-phosphorylated Rb isoforms that are present in early G1 phase and showed that each has differential binding preferences to E2F family members. These results parallel other signaling proteins where phosphorylation of specific sites enhance or decrease binding to cellular targets.

Cyclin D:Cdk4/6 complexes exclusively mono-phosphorylate Rb in early G1 phase

Based on the constitutive cyclin D:Cdk4/6 activity in early G1 phase when Rb was exclusively mono-phosphorylated (Figure 1B), cyclin D:Cdk4/6 became a prime candidate for the Rb mono-phosphorylating kinase. To dissect the role of cyclin D:Cdk4/6 to phosphorylate Rb, we used triple knockout (TKO) cyclin D genetic deletion in mouse embryonic fibroblasts (MEFs) (Choi et al., 2012). MEFs containing a deleted cyclin D2 gene and homozygous LoxP cyclin D1f/f and D3f/f genes were treated with Adenovirus Cre recombinase to generate TKO cyclin D MEFs. TKO cyclin D MEFs continuously cycled and contained hyper-phosphorylated Rb by 1D SDS-PAGE (Figure 3A, Figure 3—figure supplement 1). 2D IEF of Rb from asynchronously cycling parental D1+/D3+ MEFs showed the presence of both mono-phosphorylated Rb and hyper-phosphorylated Rb isoforms (Figure 3B). In contrast, 2D IEF of Rb from cycling TKO cyclin D MEFs contained un-phosphorylated Rb and hyper-phosphorylated Rb, with no mono-phosphorylated Rb detected (Figure 3B). Moreover, contact inhibited early G1 phase arrested (+FBS) parental D1+/D3+ MEFs contained only mono-phosphorylated Rb, whereas contact inhibited (+FBS) TKO cyclin D MEFs contained only un-phosphorylated Rb (Figure 3B). Retroviral expression of cyclin D1 in contact inhibited TKO cyclin D MEFs resulted in the appearance of mono-phosphorylated Rb (Figure 3B).

Figure 3 with 1 supplement see all
Cyclin D:Cdk/6 is the Rb mono-phosphorylation kinase.

(A) Immunoblot of cyclin D1, D3, Rb in cycling parental D1+/D3+ MEFs and triple knockout (TKO) cyclin D MEFs. (B) 2D IEF Rb immunoblot from cycling parental D1+/D3+ MEFs and TKO cyclin D MEFs, and contact inhibited early G1 phase arrested (+FBS) parental D1+/D3+ MEFs and TKO cyclin D MEFs plus/minus retroviral cyclin D1 expression. (C) 2D IEF Rb immunoblot from serum deprived G0 arrested (−FBS) and released (+FBS) HFFs plus control DMSO, Cdk4 inhibitor (PD0332991) or retroviral p16 expression. (D) 2D IEF Rb immunoblot from serum deprived G0 arrested (−FBS) and released (+FBS) p16-deleted U2OS tumor cells or released (+FBS) plus TET-induced p16 expression. (E, F) 1D SDS-PAGE (E) and 2D IEF (F) Rb immunoblot of G2/M phase nocodazole arrested (Noc.) and released U2OS cells plus DMSO (con) or Cdk4 inhibitor (PD0332991). (G, H) 1D SDS-PAGE (G) and 2D IEF (H) Rb immunoblot of G2/M phase nocodazole arrested (Noc.) and released HeLa cells plus DMSO (con) or Cdk4 inhibitor (PD0332991). (I) Late G1 phase primary HFFs were treated with Cdk2 inhibitor Roscovitine [15 μM] or control (DMSO) and analyzed by 1D SDS-PAGE Rb immunoblot, anti-Cdk4/6 and anti-Cdk2 immunoprecipitation-kinase assays. (J) 2D IEF Rb immunoblot from late G1 phase HFFs treated with dose curve of Cdk2 inhibitor Roscovitine or control (DMSO).

https://doi.org/10.7554/eLife.02872.007

To further test the notion that cyclin D:Cdk4/6 is the Rb mono-phosphorylating kinase, we treated serum deprived G0 arrested (−FBS) and restimulated (+FBS) HFFs to enter early G1 phase with a selective Cdk4/6 inhibitor (PD0332991) (Fry et al., 2004). Consistent with TKO cyclin D MEFS, treatment of HFFs with the Cdk4/6 inhibitor at restimulation (+FBS) resulted in the presence of un-phosphorylated Rb, whereas control DMSO-treated cells contained mono-phosphorylated Rb (Figure 3C). Likewise, specific inhibition of cyclin D:Cdk4/6 complexes by retroviral expression of the Cdk4/6 inhibitor p16 resulted in the presence of un-phosphorylated Rb (Figure 3C). Furthermore, induction of p16 in serum deprived G0 arrested (−FBS) and restimulated (+FBS) U2OS cells (Jiang et al., 1998) also resulted in the presence of un-phosphorylated Rb, whereas control cells (repressed p16) contained mono-phosphorylated Rb (Figure 3D). Collectively, these results from three independent approaches (genetic TKO cyclin D MEFs, expression of p16, treatment with Cdk4/6 inhibitor) in three different cell types (MEFs, HFFs, U2OS) confirmed that cyclin D:Cdk4/6 was the Rb mono-phosphorylating kinase in vivo.

Rb remains hyper-phosphorylated in M phase and is dephosphorylated by activation of the PP1 phosphatase as cells exit mitosis into the next early G1 phase (Ludlow et al., 1993). To ascertain if phosphatase activity dephosphorylates Rb to mono-phosphorylated or un-phosphorylated isoforms, we arrested U2OS cells at G2/M phase by addition of nocodazole, a microtubule depolymerizer, and detected only hyper-phosphorylated Rb (Figure 3E,F). After nocodazole washout and release of U2OS cells into early G1 phase for 4 hr, all of the hyper-phosphorylated Rb was converted to mono-phosphorylated Rb. However, release of U2OS cells from the nocodazole arrest in the presence of the Cdk4/6 inhibitor (PD0332991) resulted in the exclusive appearance of un-phosphorylated Rb (Figure 3E,F). Likewise, nocodazole block and release of HeLa cells in the presence of the Cdk4/6 inhibitor (PD0332991) resulted in the presence of only un-phosphorylated Rb (Figure 3G,H). These results determined that as cells exit mitosis, Rb is fully dephosphorylated to un-phosphorylated Rb, and then rapidly mono-phosphorylated by cyclin D:Cdk4/6 complexes in early G1 phase.

Previous studies from our lab and many others have shown that Rb becomes inactivated by hyper-phosphorylation at the late G1 Restriction point and remains hyper-phosphorylated throughout late G1 phase, S phase, G2 phase, and M phases (DeCaprio et al., 1989; Mittnacht et al., 1994; Ezhevsky et al., 2001). Hyper-phosphorylated Rb first appears concomitant with activation of cyclin E:Cdk2 complexes (Figure 1B). To ascertain the role of cyclin E:Cdk2 as the initial Rb hyper-phosphorylating kinase, we analyzed Rb from contact inhibited and released HFFs that were allowed to enter late G1 phase at 12 hr. We found that the vast majority of Rb was hyper-phosphorylated, with active Cdk2 and active Cdk4/6 complexes (Figure 3I). Selective inhibition of Cdk2 by 15 μM roscovitine, a Cdk2 ATP competitive inhibitor, resulted in no Cdk2 activity, continued Cdk4/6 activity and the presence of mono-phosphorylated Rb (Figure 3I,J). Titration of roscovitine from 2 μM to 15 μM resulted in a dose-dependent appearance of intermediate phosphorylated Rb isoforms (Figure 3J), suggesting that unlike cyclin D:Cdk4/6, cyclin E:Cdk2 is a processive Rb kinase. These observations are entirely consistent with our previous reports that cyclin E:Cdk2 complexes are the initial Rb hyper-phosphorylating kinase at the late G1 Restriction Point (Ezhevsky et al., 1997, 2001; Haberichter et al., 2007).

Mono-phosphorylated Rb is functionally active during a DNA damage response

Although Rb regulates many processes in early G1 phase (Burkhart and Sage, 2008), to ascertain if mono-phosphorylated Rb was functionally active, we focused on Rb's regulation of a DNA damage response cell cycle arrest (Harrington et al., 1998; Brugarolas et al., 1999; Knudsen et al., 2000; Avni et al., 2003). Treatment of cycling MEFs with a sub-lethal dose (100 ng/ml) of doxorubicin, a DNA damage-inducing topoisomerase II inhibitor, resulted in a G1 phase cell cycle arrest with constitutive cyclin D:Cdk4/6 activity, mono-phosphorylated Rb, and loss of cyclin E/A:Cdk2 activity (Figure 4A,B). Surprisingly, doxorubicin treatment of serum-deprived G0 arrested MEFs that contained un-phosphorylated Rb and no cyclin D:Cdk4/6 activity, resulted in induction of cyclin D1 and Cdk6, activation of cyclin D:Cdk4/6 complexes and Rb mono-phosphorylation (Figure 4C,D). Although several studies have suggested that Rb is phosphorylated during a DNA damage response by non-Cdk kinases, including Chk1/2 and Aurora B (Inoue et al., 2007; Nair et al., 2009), inhibition of Cdk4/6 activity by retroviral p16 expression in doxorubicin-treated MEFs resulted in the exclusive presence of un-phosphorylated Rb (Figure 4B,D), thereby excluding the involvement of other kinases. Together, these observations demonstrated that in response to DNA damage, cells select for mono-phosphorylated Rb by activating cyclin D:Cdk4/6 complexes.

DNA damage induces cyclin D:Cdk4/6 activity and mono-phosphorylated Rb.

(A) Asynchronously cycling MEFs (+FBS) treated with Doxorubicin (+Doxo, 100 ng/ml) were analyzed by 1D SDS-PAGE Rb immunoblot, anti-Cdk4/6 and anti-Cdk2 immunoprecipitation-kinase assays. (B) 2D IEF Rb immunoblot from asynchronously cycling MEFs (+FBS) treated with control or Doxorubicin (+Doxo) or Doxorubicin plus retroviral p16 (+Doxo/+p16) expression. (C) Serum-deprived G0 arrested MEFs (−FBS) treated with Doxorubicin (+Doxo/−FBS) were immunoblot analyzed for cyclin D1, Cdk4, Cdk6, and Cdk4/6 immunoprecipitation-kinase activity. Note activation of cyclin D:Cdk4/6 in absence of serum growth factors. (D) 2D IEF Rb immunoblot from serum-deprived G0 arrested MEFs (−FBS) treated with control or Doxorubicin (+Doxo) or Doxorubicin plus retroviral p16 (+Doxo/+p16) expression.

https://doi.org/10.7554/eLife.02872.009

We developed a genetic system to test if un-phosphorylated Rb and/or mono-phosphorylated Rb were functionally active to mediate the DNA damage cell cycle arrest checkpoint. Parental homozygous LoxP Rbf/f MEFs (Marino et al., 2000) were treated with TAT-Cre protein (Wadia et al., 2004) to delete Rb (Rb−/−), followed by infection with carefully engineered and titered wild type (WT) Rb-HA or non-phosphorylatable ΔCdk Rb-HA retroviruses (Figure 5A). This approach resulted in an acute loss of endogenous Rb protein combined with simultaneous replacement by ectopic Rb at physiologic levels (Figure 5A). Treatment of Rb-deleted MEFs expressing ectopic WT Rb-HA with doxorubicin resulted in the presence of mono-phosphorylated Rb, whereas Rb-deleted MEFs expressing ectopic ΔCdk Rb-HA contained un-phosphorylated Rb (Figure 5B).

Figure 5 with 1 supplement see all
Mono-phosphorylated Rb is active during a DNA damage response.

(A) Rb immunoblot of contact inhibited parental MEFs, conditionally deleted Rb−/− MEFs, and retrovirally-expressed wild type (WT) Rb-HA or non-phosphorylatable ΔCdk Rb-HA in deleted Rb−/− MEFs. (B) 2D IEF Rb immunoblot of cycling and doxorubicin (+Dox) (100 ng/ml) treated WT Rb-HA MEFs, and ΔCdk Rb-HA MEFs in deleted Rb−/− background. (C) Microarray heat map of mRNA levels from early G1 phase Rb−/− MEFs, WT Rb-HA MEFs, and ΔCdk Rb-HA MEFs compared to parental MEFs treated with Doxorubicin (+Doxo) for 3 hr. Only genes increased >1.6-fold are shown. (D) Focused mRNA expression analysis of E2F target genes and p21 control gene from (C). (EG) qRT-PCR mRNA analysis of endogenous E2F-dependent target genes, cdc6 (E) and DHFR (F), and a non-E2F control gene, p21 (G), from parental MEFs (con), Rb−/− MEFs, WT Rb-HA MEFs, and ΔCdk Rb-HA MEFs in deleted Rb−/− background treated with doxorubicin (+Doxo). Mean values were normalized to β2-microglobulin levels, reported as fold change from parental MEFs (con). Error bars indicate SEM from three independent experiments. (H and I) Quantification of percent tetraploid (>4n DNA) nuclei in parental MEFs (con), Rb−/− MEFs, WT Rb-HA MEFs, and ΔCdk Rb-HA MEFs in deleted Rb−/− background four days after treatment with Doxorubicin (+Doxo) (H) or 2 days post-treatment with ionizing radiation (20 grays) (I). Error bars indicate SEM from three independent experiments.

https://doi.org/10.7554/eLife.02872.010

We next analyzed the ability of WT Rb-HA and ΔCdk Rb-HA to regulate global transcription during an acute DNA damage response. Parental MEFs expressing endogenous Rb, Rb-deleted MEFS, and Rb-deleted MEFS expressing either WT Rb-HA or ΔCdk Rb-HA were contact arrested in early G1 phase (+FBS) and released for 4 hr, then treated with a sub-lethal dose of doxorubicin (100 ng/ml) for 3 hr and analyzed for whole genome transcriptional changes (Figure 5C). Rb is a transcriptional repressor and Rb-deleted MEFs showed a >1.6x increase in expression of 173 genes, primarily involved in DNA replication (24%), cell cycle control (20%), and regulation of transcription (18%) (Table 1). Expression of physiologic levels of mono-phosphorylated WT Rb-HA in Rb-deleted cells restored repression of many of these genes, especially E2F target genes (Figure 5C,D; Figure 5—figure supplement 1). However, expression of un-phosphorylated ΔCdk Rb-HA at physiologic levels failed to repress genes and gave a pattern of global transcriptional deregulation similar to Rb-deleted MEFs, suggesting that un-phosphorylated Rb was functionally inactive during a DNA damage response checkpoint during early G1 phase. Further qRT-PCR analysis of two strong E2F target genes, DHFR and cdc6, showed similar levels of deregulation in both Rb-deleted and un-phosphorylated ΔCdk Rb-HA MEFs, whereas WT Rb-HA repressed both of these genes (Figure 5E–G). A non-Rb regulated gene, p21, showed no difference between all three genotypes. Rb-deleted (Rb−/−) MEFs also failed to prevent the appearance of tetraploid cells several days after treatment with either doxorubicin or ionizing radiation (20 Grays) (Figure 5H,I). Consistent with the inability to regulate transcriptional control, un-phosphorylated ΔCdk Rb-HA MEFs showed similar high levels of tetraploid cells in response to DNA damage as Rb-deleted (Rb−/−) MEFs. In contrast, WT Rb-HA expression rescued the tetraploid phenotype to levels near parental MEFs expressing endogenous wild type Rb (Figure 5H,I). These observations demonstrated that cells undergoing a DNA damage response activate cyclin D:Cdk4/6 to generate biologically active, mono-phosphorylated Rb, whereas un-phosphorylated was functionally inactive for regulating E2F transcription and preventing the appearance of tetraploid cells.

Table 1

Mono-phosphorylated Rb is active during a DNA damage response

https://doi.org/10.7554/eLife.02872.012
InducedRepressed
 DNA replication24% Localization18%
 Cell cycle20% Post-translational protein modification10%
 Regulation of transcription18% Biosynthetic process9%
 Organelle organization and biogenesis12% Organelle organization and biogenesis8%
 Response to stress12% Intracellular signaling cascade8%
 DNA repair8% Proteolysis6%
 DNA packaging7% Catabolic process6%
 Macromolecular complex assembly6% Cell cycle6%
 Cellular component assembly6% Nervous system development6%
 Chromatin assembly6% Response to external stimulus4%
 Response to wounding3%
 Dephosphorylation2%
  1. Gene ontology of mRNA differences showing a >1.6-fold increase/decrease level by microarray analysis between parental MEFs and Rb−/− MEFs treated with 100 ng/ml doxorubicin for 3 hr after release from contact inhibition.

Un-phosphorylated Rb promotes cell cycle exit and differentiation

The above results demonstrated that un-phosphorylated Rb was non-functional during a DNA damage response. However, serum-deprived G0 arrested HFFs and U2OS cells contained un-phosphorylated Rb (Figure 1E,G; Figure 3D), as do quiescent G0 peripheral blood lymphocytes (PBLs) (Ezhevsky et al., 2001). Moreover, other studies have documented a role for Rb in cell cycle exit and differentiation, including proper myogenic development as myoblasts exit the cell cycle into G0 (Gu et al., 1993; Zacksenhaus et al., 1996; Chen and Wang, 2000; Sage et al., 2003; Blais et al., 2007). Together, these observations suggested a potential functional role for un-phosphorylated Rb during cell cycle exit and differentiation. To evaluate the phosphorylation status of Rb during differentiation, we used the well-established C2C12 myoblast to myotube differentiation system (Blais et al., 2005). Asynchronous cycling C2C12 myoblasts grown in high mitogen media (FBS) contained both mono-phosphorylated Rb and hyper-phosphorylated Rb with no detectable un-phosphorylated Rb (Figure 6A,B). However, addition of low mitogen, differentiation media induced expression of myotube specific myogenin and resulted in the exclusive presence of un-phosphorylated Rb at day 2, concomitant with loss of cyclin D:Cdk4/6 kinase activity and expression of p18, a Cdk4/6-specific inhibitor (Halevy et al., 1995; Franklin and Xiong, 1996; Wang and Walsh, 1996; Zhang et al., 1999) (Figure 6B–D). We also observed the exclusive appearance of un-phosphorylated Rb when human HL60 promyelocytic cells were induced to undergo differentiation by addition of retinoic acid (Figure 6—figure supplement 1A,B).

Figure 6 with 1 supplement see all
Un-phosphorylated Rb promotes cell cycle exit and differentiation.

(A) Rb immunoblot of cycling C2C12 myoblasts (Asynch), and after 2 days in differentiation medium (Diff). (B) 2D IEF Rb immunoblot from cycling C2C12 myoblasts (Asynch) and after 2 days in differentiation medium (Diff). (C) Cdk4/6 immunoprecipitation-kinase assay of cycling C2C12 myoblasts (0) and at 1 and 2 days post-addition of differentiation medium (Diff). Negative (neg) control, irrelevant antibody. (D) Myogenin immunoblot of cycling C2C12 myoblasts (Asynch), and after 2 days in differentiation medium (Diff). (E) Immunoblot of endogenous Rb, and retroviral expressed wild type (WT) Rb-HA or ΔCdk Rb-HA in C2C12 myoblasts co-infected with short hairpin (sh) RNAi retroviruses targeting endogenous Rb (3' UTR) or scrambled (Scr) control. (F and G) Proliferation analysis (number of nuclei) of C2C12 myoblasts co-infected with short hairpin (sh) RNAi retroviruses targeting endogenous Rb (3' UTR) or scrambled (Scr) control, and wild type (WT) Rb-HA or ΔCdk Rb-HA retroviruses. Cells were stained with Hoechst 33342 DNA dye, visualized by microscopy (F) and quantified by flow cytometry (G) (number of nuclei x 103) at 2 days post-addition of differentiation medium. Error bars indicate SEM. (H) qRT-PCR mRNA analysis of Mcm3 DNA replication factor in C2C12 myoblasts treated as above (G) for 2 days in differentiation media. Mean values were normalized to β2-microglobulin levels and reported as fold change from C2C12 myotubes expressing endogenous Rb (ScrshRNA). Error bars indicate SEM from three independent experiments.

https://doi.org/10.7554/eLife.02872.013

To directly test for a role of un-phosphorylated Rb in regulating cell cycle exit and differentiation in myoblasts, we devised a strategy similar to the MEF DNA damage response approach used above. Endogenous Rb from C2C12 myoblasts was knocked down by shRb or control shScramble (Scr) RNAi retroviruses, followed by retroviral physiologic expression of WT Rb-HA or ΔCdk Rb-HA (Figure 6E). As per the method of Blais et al. (2007), the efficiency of cell cycle exit was evaluated 2 days post-addition of low mitogen differentiation media by counting the number of nuclei (Figure 6F–H). Reduction of Rb levels by shRNAi resulted in an increased proliferation index (number of nuclei), and increased expression of Mcm3 and Mcm5 (markers of DNA replication) (Figure 6F–H, Figure 6—figure supplement 1C). However, physiologic expression of WT Rb-HA compensated for the reduction in endogenous Rb by bringing the proliferation index back to the shScrambled RNAi control. Strikingly, physiologic expression of ΔCdk Rb-HA resulted in a dramatic reduction of proliferation as cells prematurely exited the cell cycle and decreased Mcm3 and Mcm5 levels (Figure 6F–H; Figure 6—figure supplement 1C). Thus, in contrast to the DNA damage response where un-phosphorylated Rb was non-functional, these observations demonstrated that un-phosphorylated Rb was functionally active to drive cell cycle exit and differentiation of myoblasts into myotubes.

Discussion

For the last 20 years, the key tenet of the prevailing model of G1 cell cycle progression proposed that cyclin D:Cdk4/6 complexes inactivated Rb by progressive multi-phosphorylation, termed hypo-phosphorylation, resulting in the gradual release of E2F transcription factors that drive cells into late G1 phase. This notion was reinforced when tumor cells expressing wild-type Rb were found to have genetic and epigenetic alterations of the p16 tumor suppressor gene or oncogenic expression of cyclin D1, D2, D3, Cdk4, and Cdk6 genes, which became known as the ‘p16-cyclin D-Rb’ pathway (Sherr, 1994; Sherr and McCormick, 2002; Burkhart and Sage, 2008; Paternot et al., 2010; Henley and Dick, 2012; Choi and Anders, 2013). Further reinforcing this notion were experiments utilizing supra-physiologic overexpression of D-type cyclins and Cdk4/Cdk6 that inactivated Rb and drove cells into S phase. Likewise, experiments overexpressing p16, a Cdk4/6 inhibitor, arrested cells in a 2n DNA content and were interpreted to confirm the notion that cyclin D:Cdk4/6 complexes inactivated Rb. Moreover, the large number of tryptic phospho-peptides of ‘hypo-phosphorylated’ Rb from early G1 cells reported by Mittnacht et al. (1994) was unknowingly misinterpreted and further reinforced the notion that cyclin D:Cdk4/6 complexes inactivate Rb by progressive multi-phosphorylating, hypo-phosphorylation. Although there was a complete absence of rigorous biochemical evidence as to the extent of phosphate numbers or kinetics on what was loosely termed hypo-phosphorylated Rb, the notion that cyclin D:Cdk4/6 inactivated Rb by progressive multi-phosphorylating, hypo-phosphorylation was solidified in the 1990s as the model of G1 cell cycle progression.

In sharp contrast to the prevailing model, we had previously performed kinetic analyses from highly synchronized normal cells and p16-deficient tumor cells, and found that cyclin D:Cdk4/6 was constitutively active throughout all of the early G1 phase at the same time points that Rb was actively binding E2Fs and repressing E2F target gene expression (Ezhevsky et al., 1997, 2001; Haberichter et al., 2007). Consequently, we suspected that cyclin D:Cdk4/6 complexes were not inactivating Rb, but may, in fact, be activating Rb by phosphorylation. The key to understanding the relationship between Rb and cyclin D:Cdk4/6 complexes was developing the ability to quantitatively separate all Rb isoforms by 2D IEF combined with the generation of Rb phosphorylation standards. During the course of this study, we performed hundreds of 2D IEFs on Rb from 11 independent normal and tumorigenic cell types under conditions of asynchronous cycling cells, cells arrested in G0, early G1, late G1 or G2/M phases, and cells that were arrested/released and followed kinetically. Under all of these conditions and cell types, we found that Rb was exclusively mono-phosphorylated throughout all of early G1 phase in both normal and tumor cells, and hyper-phosphorylated in late G1, S, G2, and M phases. In fact, we found no biochemical evidence to support the prevailing G1 cell cycle model that cyclin D:Cdk4/6 progressively hypo-phosphorylates Rb. Moreover, using three independent approaches to dissect cyclin D:Cdk4/6 function on Rb, namely: triple cyclin D genetic deletion, addition of a Cdk4/6-specific chemical inhibitor, and p16 expression, we determined that cyclin D:Cdk4/6 is the Rb mono-phosphorylating kinase (Figure 7). Given that mono-phosphorylated Rb is the only isoform of Rb present in early G1 phase, by definition, some, most or all of the mono-phosphorylated Rb isoforms must be biologically active. Consequently, it was not too surprising that mono-phosphorylated Rb was the active Rb isoform mediating a DNA damage response cell cycle arrest and regulating global transcription. However, we note the unanticipated observation that exposure of quiescent G0 (−FBS) primary cells, containing no cyclin D:Cdk4/6 activity, to DNA damaging agents induced and activated cyclin D:Cdk4/6 complexes to mono-phosphorylate Rb in the absence of serum growth factors. This observation is consistent with a role for cyclin D:Cdk4/6 complexes in the DNA damage response checkpoint (Choi et al., 2012), but also raises a cautionary concern for a potential increase of genomic DNA damage in the normal cells of patients being simultaneously treated with a cyclin D:Cdk4/6 inhibitor and a DNA damaging chemotherapy or ionizing radiation.

Revised working model of G1 cell cycle progression.

Un-phosphorylated Rb regulates G0 cell cycle exit and differentiation. Growth factor signaling and DNA damage stimulate activation of cyclin D:Cdk4/6 complexes that diversify Rb into 14 mono-phosphorylated isoforms that independently bind specific cellular factors to regulate early G1 phase functions and the DNA damage response. Cyclin D:Cdk4/6 mono-phosphorylation of Rb inactivates un-phosphorylated Rb G0 functions and thereby prevents cells from exiting the cell cycle. Activation of cyclin E:Cdk2 complexes inactivates all 14 mono-phosphorylated Rb isoforms by hyper-phosphorylation (>12x phosphates) at the late G1 Restriction Point. Cyclin A:Cdk2 and cyclin B:Cdk1 maintain Rb in an inactive hyper-phosphorylated state during S, G2 and M phases. As cells complete cytokinesis, hyper-phosphorylated Rb is de-phosphorylated by phosphatases and rapidly mono-phosphorylated by cyclin D:Cdk4/6 complexes. We speculate that an unknown metabolic sensor is upstream of cyclin E:Cdk2 activation.

https://doi.org/10.7554/eLife.02872.015

The Rb gene is transcribed and spliced into a single 4.7 kb mRNA composed of 27 coding exons that does not undergo appreciable alternative splicing and encodes a single 105 kDa protein (Burkhart and Sage, 2008). Although the complete structure of Rb has yet to be solved, several groups have recently solved the core structure as an intra-strand pseudo-dimer of dimers with the Cdk sites present on loops between structured regions or on the C-terminus abutting the B-box (Burke et al., 2012; Lamber et al., 2013) (Figure 1A). Based on the binding preferences of individual Rb mono-phosphorylated isoforms to specific E2F transcription factors, our data suggest that the generation of 14 mono-phosphorylated Rb isoforms may serve as a mechanism to post-translationally functionally diversify Rb in early G1 phase from a single un-phosphorylated isoform in G0. In addition to E2F transcription factors, Rb has also been shown to bind to over 100 additional cellular proteins (Morris and Dyson, 2001), leaving open the potential for differential binding preferences of mono-phosphorylated Rb to specific cellular targets. Excluding hyper-phosphorylated Rb, we were surprised at the complete absence of any multi-phosphorylated Rb isoforms. This raised the mechanistic question of how does cyclin D:Cdk4/6 complexes place one, and only one, phosphate on Rb while leaving the remaining 13 Cdk sites un-phosphorylated? While this will require extensive structural analyses beyond the scope of our study, we speculate that the substrate recognition of Rb by cyclin D's N-terminal LxCxE motif weak binding to Rb's pocket domain (Dowdy et al., 1993) vs cyclins E and A avid binding to four C-terminal R/KxL substrate motifs (Adams et al., 1999) outside of the pocket likely serves as the defining mechanism between Rb mono-phosphorylation and Rb hyper-phosphorylation (Figure 1A). In this hypothesis, cyclin E/A:Cdk2's strong binding to the C-terminal tail of Rb would allow access to all 14 Cdk sites on Rb even when transcription factors and chromatin remodeling factors were bound to Rb's pocket and N-terminal binding sites. This also allows for a simultaneous switch-like inactivation of all 14 mono-phosphorylated Rb isoforms by one processive hyper-phosphorylation mechanism. We believe that the utilization of the same phosphorylation sites for the activation and inactivation of a protein, albeit with a >12-fold increased phosphate stoichiometry, is an unprecedented mechanism in the literature, but one that also likely applies to Rb-related genes p107 and p130.

Our study addresses several critical problems arising from numerous biochemical analyses of Rb phosphorylation going back more than 20 years. The results presented here fundamentally change the understanding of G1 cell cycle regulation to show that cyclin D:Cdk4/6 activates Rb for binding cellular targets during early G1 phase by generating 14 independent mono-phosphorylated Rb isoforms. Given that the majority of human tumors contain wild-type Rb, but select for deregulated cyclin D:Cdk4/6 activity (Sherr and McCormick, 2002; Burkhart and Sage, 2008; Knudsen and Knudsen, 2006; Choi and Anders, 2013), we hypothesize that the oncogenic activation of cyclin D:Cdk4/6 results in Rb mono-phosphorylation to drive quiescent G0 cells into a more metabolically active, but early G1 phase arrested phenotype (Figure 8). By constitutively mono-phosphorylating Rb, the nascent neoplastic cell avoids cell cycle exit and differentiation mediated by un-phosphorylated Rb, and also maintains a high level of metabolism. This notion is entirely consistent with the observed subtle and highly tolerated cancer predisposing mutations of p16 deletion and cyclin D overexpression in mouse models that avoid activation of oncogene-induced apoptosis (Burkhart and Sage, 2008). The net effect is a subtle, but irreversible, oncogenic step forward. While our study determined the role of cyclin D:Cdk4/6 in mono-phosphorylating Rb, it leaves wide open the question of what the rate-limiting switch-like mechanism is to activate cyclin E:Cdk2, the first domino in Rb inactivation. Cyclin D:Cdk4/6 activity combined with other signal transduction pathway mutations contributes to increased cellular metabolism that we speculate is monitored by an unknown metabolic sensor. Once the metabolic threshold has been exceeded, the sensor activates cyclin E:Cdk2 resulting in Rb inactivation by hyper-phosphorylation, induction of E2F target gene transcription and progression across the Restriction Point into late G1 phase (Haberichter et al., 2007). We are currently investigating the mechanics of this putative mechanism and the identity of the metabolic sensor.

Deregulated cyclin D:Cdk4/6 in cancer mono-phosphorylates Rb to prevent cell cycle exit.

Deregulation of cyclin D:Cdk4/6 activity in cells occurs by a variety of mechanisms, including: p16 deletion, cyclin D1, D2 and D3 amplification or overexpression, and mutation or overexpression of Cdk4 or Cdk6. Cyclin D:Cdk4/6 mono-phosphorylation of Rb simultaneously inactivates Rb's G0 functions and activates Rb's early G1 phase functions thereby driving cells from a low metabolism G0 quiescence into a high metabolism early G1 arrested state that also prevents subsequent cell cycle exit or differentiation. Similar to p53 mutations and Bcl2 overexpression, deregulated cyclin D:Cdk4/6 activity is a well tolerated priming oncogenic mutation that avoids activation of oncogene-induced apoptosis. The net effect is a subtle, but irreversible, oncogenic step forward. We predict that additional oncogenic and metabolic pathways ultimately converge on and activate cyclin E:Cdk2 complexes to inactivate Rb by hyper-phosphorylation at the Restriction Point and drive cells into late G1 phase.

https://doi.org/10.7554/eLife.02872.016

Materials and methods

Cell culture

Cells were G0 arrested by serum deprivation for 5 days, followed by addition of 10% FBS. Cells were plated at high density in 10% FBS to contact inhibit arrest in early G1 phase for 48 hr, followed by replating at low density in 10% FBS. DNA damage was induced by addition of 100 ng/ml doxorubicin (Sigma, St. Louis, MO) or exposure to 20 Grays of ionizing radiation. MEFs were prepared from Rbf/f mice (Marino et al., 2000) and cyclin D1f/f/D2−/−/D3 f/f mice (Choi et al., 2012). Rb and cyclin D inactivation was performed by addition of TAT-Cre protein (Wadia et al., 2004). U2OS-p16 cells (Jiang et al., 1998) were maintained in 1 μg/ml tetracycline to repress p16 expression. C2C12 myoblasts were differentiated into myotubes by incubating with DMEM plus 2% horse serum for 2 days.

Generation of constructs and retroviruses

Human RbΔCDK−HA and murine RbΔCDK−HA were generated by changing all 15 Ser/Thr Cdk acceptor sites to Ala, with Ser567 and S561, respectively, left unaltered, with a HA tag placed on the N-terminus and C-terminus, respectively, and expressed from pCMV. Human Rb single Cdk sites were generated by individually adding back each single Cdk site to RbΔCDK−HA. Rb2xCdk retained T373, S811; Rb3xCdk retained T373, S612, S811; Rb6xCdk retained the N-terminal Cdk sites; Rb9xCdk retained spacer and C-terminal Cdk sites. Murine RbWT−HA and RbΔCdk−HA MSCV retroviruses were generated from transfected HEK 293 cells and stored at −80°C. E2F constructs were expressed from pCMV and contained a C-terminal Myc tag. The Rb shRNA vector was generated by inserting a 3′ UTR region of the endogenous Rb mRNA (GCTTTGAACTGAAGACTAT) into pSM2c-scramble (Stegmeier et al., 2005).

2D IEF

2D-IEF was performed as described (Ezhevsky et al., 2001) by immunoprecipitating Rb and eluting in 7 M urea/2 M thiourea/2% CHAPS (pH 8.4), then loading onto the acidic end of a 3–10 immobiline strips (GE Healthcare) with the current ramped up from 200 V for 2 hr, 500 V for 1 hr, 800 V for 1 hr, 1000 V for 0.5 hr, 1200 V for 0.5 hr, 1400 V for 0.5 hr, 1600 V for 0.5 hr, 1800 V for 2.5 hr, and 2000 V for 2.5 hr. Second dimension was performed by soaking IEF strip in 2% SDS/6 M urea/75 mM Tris (pH 8.8), 29% (wt/vol) glycerol, and placing the strip on top of a 6% SDS-PAGE containing a single large well to accommodate the IEF strip with Mw marker side wells.

Immunoprecipitations, immunoblotting and kinase assays

Co-immunoprecipitations were performed as described (Ezhevsky et al., 1997) using anti-Rb (G3-245, BD Pharmingen, San Jose, CA), anti-HA (3F10, Roche, Basel, Switzerland), anti-Myc (9E10, Developmental Studies Hybridoma Bank, Iowa City, IA), or anti-E1a (M73). Immunoblotting was performed as described (Ezhevsky et al., 1997) using anti-Rb (G3-245, BD Pharmingen), anti-HA (3F10, Roche), anti-actin (C4, Abcam), anti-E1a (13-S5; Santa Cruz), and anti-Myc (9E10, Developmental Studies Hybridoma Bank) antibodies. Rb immunoblots were performed using 6% SDS-PAGE for separation or 10% SDS-PAGE for quantification. All immunoblots were quantified utilizing ChemiDoc XRS (Bio-Rad, Hercules, CA) sub-saturating linear signals. Rb phospho-specific antibodies: T356-PO4 (AB4780, Abcam, Cambridge, England), S608-PO4 (2181, Cell Signaling, Danvers, MA), S612-PO4 (OPA1-03891, Thermo Scientific, Waltham, MA), S780-PO4 (3590, Cell Signaling), S807-PO4/S811-PO4 (9308, Cell Signaling), T821-PO4 (AB4787, Abcam), T826-PO4 (AB4779, Abcam), T821-PO4/T826-PO4 (sc-16669, Santa Cruz), T373 (AB52975, Abcam), S249-PO4/T252-PO4 (sc-16671, Santa Cruz). Immunoprecipitation-kinase assays were performed as described (Ezhevsky et al., 1997) using anti-CDK4 (C22), anti-CDK6 (C21), and anti-Cdk2 (M2) polyclonal antibodies (Santa Cruz).

qRT-PCR and microarray analysis

qRT-PCR was performed as described (Eguchi et al., 2009) using 6-FAM labeled TaqMan probes (Dhfr, 00515663; Cdc6, 00488573; Ccna2, 01282245; p21, 00432448; β2M, 00437762; Mcm3, 00801867; Mcm5, 00484839; Life Technologies, Grand Island, NY). Mean values of triplicate samples were normalized to beta-2-microglobulin. Whole-genome microarray analysis was performed as described (Eguchi et al., 2009) using MouseWG-6 v2.0 BeadChips (Illumina, San Diego, CA) at Biogem core (UCSD). Heat maps were created with Cluster 3.0 and Java TreeView 1.1.3 and gene ontology classifications were based on DAVID Bioinformatics Resources (Dennis et al., 2003; Huang da et al., 2009). Full microarray data set has been submitted to GEO (GSE56453) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56453.

References

  1. 1
    Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes
    1. PD Adams
    2. X Li
    3. WR Sellers
    4. KB Baker
    5. X Leng
    6. JW Harper
    7. Y Taya
    8. WG Kaelin Jnr
    (1999)
    Molecular and Cellular Biology 19:1068–1080.
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
    DAVID: Database for Annotation, Visualization, and Integrated Discovery
    1. G Dennis Jnr
    2. BT Sherman
    3. DA Hosack
    4. J Yang
    5. W Gao
    6. HC Lane
    7. RA Lempicki
    (2003)
    P3, Genome Biology, 4, Epub 2003 Apr 3, 10.1186/gb-2003-4-5-p3.
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
    1. DW Fry
    2. PJ Harvey
    3. PR Keller
    4. WL Elliott
    5. M Meade
    6. E Trachet
    7. M Albassam
    8. X Zheng
    9. WR Leopold
    10. NK Pryer
    11. PL Toogood
    (2004)
    Molecular Cancer Therapeutics 3:1427–1438.
  20. 20
  21. 21
  22. 22
  23. 23
    pRB plays an essential role in cell cycle arrest induced by DNA damage
    1. EA Harrington
    2. JL Bruce
    3. E Harlow
    4. N Dyson
    (1998)
    Proceedings of the National Academy of Sciences of the United States of America 95:11945–11950.
    https://doi.org/10.1073/pnas.95.20.11945
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression
    1. H Jiang
    2. HS Chou
    3. L Zhu
    (1998)
    Molecular and Cellular Biology 18:5284–5290.
  29. 29
  30. 30
    Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation
    1. ES Knudsen
    2. JY Wang
    (1997)
    Molecular and Cellular Biology 17:5771–5783.
  31. 31
  32. 32
    Retinoblastoma tumor suppressor: where cancer meets the cell cycle
    1. ES Knudsen
    2. KE Knudsen
    (2006)
    Experimental Biology and Medicine 231:1271–1278.
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes
    1. AS Lundberg
    2. RA Weinberg
    (1998)
    Molecular and Cellular Biology 18:753–761.
  40. 40
  41. 41
    Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation
    1. S Mittnacht
    2. JA Lees
    3. D Desai
    4. E Harlow
    5. DO Morgan
    6. RA Weinberg
    (1994)
    The EMBO Journal 13:118–127.
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53

Decision letter

  1. Roger Davis
    Reviewing Editor; University of Massachusetts Medical School, United States

eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see review process). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled “Cyclin D:Cdk4/6 Activates Rb in Early G1 Phase by Mono-Phosphorylation” for consideration at eLife. Your article has been favorably evaluated by Tony Hunter (Senior editor), a Reviewing editor, and 3 reviewers.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

Narasimha et al. demonstrate that, contrary to dogma, cyclinD/CDK does not hypo- or hyper-phosphorylate pRb nor inactivate pRb. Their data suggest that pRb is activated in G1 phase by cyclinD/CDK dependent mono-phosphorylation at one of 14 CDK sites. Hyper-phosphorylation by cyclinE/CDK inactivates pRb to fully activate E2F-dependent transcription, which surprisingly is independent of cyclinD/CDK mono-phosphorylation. In addition their data indicates that DNA damage induced pRb activation requires cyclinD/CDK-dependent mono-phosphorylation. Finally they present data that suggests that un-phosphorylated pRb drives cell cycle exit (G0 entry) or prevents G1 entry. Based on these results they suggest a model in which an increase in cyclinD/CDK activity, observed in many cancers, 'primes' a cell for loss of cell cycle control by preventing cell cycle exit (or allowing G1 entry). This radically changes the way we think about the role of cyclinD/CDK in the regulation of pRb function.

Importantly, the data presented provide many new insights into the role of cyclinD/CDK in pRb regulation and challenge the current understanding of the role of cyclinD/CDK in proliferating, cell cycle exiting and DNA damaged cells, but also the positive feedback model in which cyclinD/CDK is the initial activator of E2F-dependent transcription resulting in accumulation of cyclinE/CDK. The experiments have been performed with care, but some of the conclusions drawn are not warranted by the data.

Given the extensive scope of the current study, the reviewers believe that the remaining issues can be adequately addressed by changes to the text of the manuscript without the need for further experimentation. Specifically:

1) The data shows that pRb is mono-phosphorylated by cyclinD in response to DNA damage, which is a major observation. However, they do not show if this is checkpoint dependent by, for example, using checkpoint protein kinase inhibitors (ATR/ATM, CHK1/CHK2). The inability to phosphorylate pRb in response to DNA damage results in activation of E2F-dependent transcription and genomic instability. They state that (line 419) the appearance of tetraploid cells indicates that the cells 'failed to activate the DNA damage checkpoint'. This is neither tested nor likely. If they want to conclude this, they should show that the checkpoint protein kinases are not activated in Rb-deleted or ΔCDK-Rb cells, which seems very unlikely. The reviewers recommend that the text of the manuscript should be revised to note these points.

2) The binding specificity of specific mono-phosphorylated pRb by certain E2Fs in Figure 2D is mentioned to be reproducible, but not shown. Can the authors elaborate on this point?

3) An alternative model for E2F-dependent transcriptional activation is not presented. The authors mention that 'at the restriction point cyclinE/CDK inactivates pRb'. Although it is beyond the scope of the paper to test alternative models for E2F-dependent transcriptional activation, the reviewers believe that this topic should be included in the discussion section of the manuscript.

https://doi.org/10.7554/eLife.02872.017

Author response

1) The data shows that pRb is mono-phosphorylated by cyclinD in response to DNA damage, which is a major observation. However, they do not show if this is checkpoint dependent by, for example, using checkpoint protein kinase inhibitors (ATR/ATM, CHK1/CHK2). The inability to phosphorylate pRb in response to DNA damage results in activation of E2F-dependent transcription and genomic instability. They state that (line 419) the appearance of tetraploid cells indicates that the cells 'failed to activate the DNA damage checkpoint'. This is neither tested nor likely. If they want to conclude this, they should show that the checkpoint protein kinases are not activated in Rb-deleted or ΔCDK-Rb cells, which seems very unlikely. The reviewers recommend that the text of the manuscript should be revised to note these points.

We thank the reviewers for pointing out our poor wording in the original text and did not intend to suggest that Rb was upstream of ATR/ATM, etc. We completely concur that the DNA damage response is intact. Our investigation centered on the downstream consequences of cells either deleted for Rb or expressing a non-phosphorylatable ΔCdk Rb (un-phosphorylated Rb) that were exposed to doxorubicin or ionizing radiation and that failed to adequately arrest resulting in high numbers of tetraploid cells. This experiment showed that mono-phosphorylated Rb, generated by cyclin D:Cdk4/6, was functional and required to prevent inappropriate cell cycle progression and E2F transcription downstream of an ATR/ATM DNA damage response. We have clarified the text accordingly.

2) The binding specificity of specific mono-phosphorylated pRb by certain E2Fs in Figure 2D is mentioned to be reproducible, but not shown. Can the authors elaborate on this point?

This specific comment was meant to reinforce that the rather subtle differences observed between E2F2 and E2F3 binding to specific mono-phosphorylated Rb isoforms was consistently observed in three independent experiments, whereas E2F1 and E2F4 showed much larger binding differences.

3) An alternative model for E2F-dependent transcriptional activation is not presented. The authors mention that 'at the restriction point cyclinE/CDK inactivates pRb'. Although it is beyond the scope of the paper to test alternative models for E2F-dependent transcriptional activation, the reviewers believe that this topic should be included in the discussion section of the manuscript.

While our study determined the role of cyclin D:Cdk4/6 in mono-phosphorylating Rb, it leaves wide open the question of what the rate-limiting switch-like mechanism is to activate cyclin E:Cdk2, the first domino in Rb inactivation. Cyclin D:Cdk4/6 activity combined with other signal transduction pathway mutations contributes to increased cellular metabolism that we speculate is monitored by an unknown metabolic sensor. Once the metabolic threshold has been exceeded, the sensor activates cyclin E:Cdk2 resulting in Rb inactivation by hyper-phosphorylation, induction of E2F target gene transcription and progression across the Restriction Point into late G1 phase. We have expanded the Discussion section to include our thoughts on cyclin E:Cdk2 activation.

In conclusion, we maintain that cyclin D:Cdk4/6 complexes strictly mono-phosphorylate Rb during early G1 phase to generate 14 independent isoforms that bind E2F1-4 and are functionally active during a DNA damage response. We also assert that there is no progressive multi-phosphorylating, hypo-phosphorylation of Rb. We believe that both the depth of analyses and the magnitude of impact on understanding G1 cell cycle progression warrants publication in eLife.

https://doi.org/10.7554/eLife.02872.018

Article and author information

Author details

  1. Anil M Narasimha

    1. Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, United States
    Contribution
    AMN, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Contributed equally with
    Manuel Kaulich and Gary S Shapiro
    Competing interests
    The authors declare that no competing interests exist.
  2. Manuel Kaulich

    1. Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, United States
    Contribution
    MK, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Contributed equally with
    Anil M Narasimha and Gary S Shapiro
    Competing interests
    The authors declare that no competing interests exist.
  3. Gary S Shapiro

    1. Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, United States
    Present address
    1. Sanofi Oncology, Cambridge, United States
    Contribution
    GSS, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Contributed equally with
    Anil M Narasimha and Manuel Kaulich
    Competing interests
    The authors declare that no competing interests exist.
  4. Yoon J Choi

    1. Department of Genetics, Harvard Medical School, Boston, United States
    2. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Contribution
    YJC, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents
    Competing interests
    The authors declare that no competing interests exist.
  5. Piotr Sicinski

    1. Department of Genetics, Harvard Medical School, Boston, United States
    2. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Contribution
    PS, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents
    Competing interests
    The authors declare that no competing interests exist.
  6. Steven F Dowdy

    1. Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, United States
    Contribution
    SFD, Conception and design, Analysis and interpretation of data, Drafting or revising the article
    For correspondence
    1. sdowdy@ucsd.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (CA169849)

  • Steven F Dowdy

Howard Hughes Medical Institute

  • Steven F Dowdy

National Institutes of Health (CA108420)

  • Piotr Sicinski

Leukemia and Lymphoma Society

  • Gary S Shapiro

National Institutes of Health (TG CA009523)

  • Anil M Narasimha

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank S Ezhevsky and J Adams for critical input; M Haas, P Hamel, S Elledge, J Baldassare, L Zhu, and the Developmental Studies Hybridoma Bank (U. Iowa) for constructs, antibodies and cell lines.

Reviewing Editor

  1. Roger Davis, Reviewing Editor, University of Massachusetts Medical School, United States

Publication history

  1. Received: March 23, 2014
  2. Accepted: May 22, 2014
  3. Accepted Manuscript published: May 29, 2014 (version 1)
  4. Version of Record published: July 1, 2014 (version 2)

Copyright

© 2014, Narasimha et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,417
    Page views
  • 939
    Downloads
  • 30
    Citations

Article citation count generated by polling the highest count across the following sources: PubMed Central, Crossref, Scopus.

Comments

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

  1. Further reading

Further reading

    1. Biochemistry
    2. Biophysics and Structural Biology
    Julia P Steringer et al.
    Research Article
    1. Developmental Biology and Stem Cells
    Cyrille Ramond et al.
    Research Article